When "no data" is the complete and final answer posts 31–60
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.
I have changed my mind on this once already, so take it as current rather than settled.
Adding the measurement that post #33 says would settle it.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
That has been true for the cases I have seen and I have not seen many.
A compound with no established assay is a compound where a certificate can say almost anything. That is not an accusation about anyone; it is a statement about what a document can carry.
When "no data" is the complete and final answer: if there is no published human data on a compound, that is the state of knowledge. Hope is not a substitute and reasoning from theory is not a substitute. That is not a reason for shame; it is the honest epistemic position.
That holds under the stated conditions and I have stated them.
On post #33 — agreed on the reasoning, with one qualification.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Collapsed as off-topic by two members at trust level 3 or above
Picking up post #37: that is the part I would want checked first.
Colour in a lyophilised cake is worth noting for the less common compounds specifically, because some of them are genuinely not white and a member expecting white will report a problem that is not one.
Taking post #37 at face value and following it one step further.
Storage guidance for the less common material is usually copied from the incretin guidance and may not apply. Where the supplier has its own stability statement, that is the one to use.
Anyone who has looked at this more carefully, please correct the record.
Worth separating two things that post #40 runs together.
A compound with no established assay is a compound where a certificate can say almost anything. That is not an accusation about anyone; it is a statement about what a document can carry.
I have said this before in a thread nobody could find, so it is worth repeating.
Post #42 answers the question as asked. The question underneath it is different.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
The honest summary for most of this subcategory: a plausible mechanism, animal data, and first-hand accounts. Saying so is more useful than assembling the accounts into something that reads like evidence.
On analysis: unusual or modified sequences are exactly where a default reversed-phase method is least likely to be appropriate. A supplier that runs everything on one gradient will produce a flattering result for something.
A partial answer, offered because a partial answer beats none.
Useful. I had the fact and not the reason, which turns out to be the important half.
Coming back to post #44, because the follow-up matters more than the original answer.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Reading a supplier's product description as a marketing document: that is exactly what it is. The hyperbole, the mechanism written as fact, the theoretical benefits stated as established benefits — all of that is marketing. Treat it as such and separate it from evidence where evidence exists.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Noted, and I have changed what I was going to do on the strength of it.
Several compounds discussed here have no published human pharmacokinetics at all. That means half-life claims in circulation were derived from an animal model or from nothing.
The interesting part of this is the exception, and I do not understand the exception.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
The evidence for this is thinner than the way I have phrased it suggests.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Post #55 answers the question as asked. The question underneath it is different.
Anyone submitting an unusual compound for testing should tell the laboratory what it is rather than what it is sold as. Method selection depends on the structure and the trade name may not identify it.
It is the sort of thing that seems obvious in retrospect and was not at the time.